New drug naderin may help patients fight infections during cancer and TB therapy

NCT ID NCT07671508

Completed Disease control Sponsor: MIPO Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tested whether adding Naderin (sodium nucleinate) to standard treatment could reduce complications in 75 patients with cancer, tuberculosis, or hepatitis C. The main group received Naderin plus standard therapy, while the control group received standard therapy alone. Results showed that Naderin shortened the duration of low white blood cell counts by 4-5 days and reduced the number of infections, suggesting it may help patients better tolerate aggressive treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Naderin (sodium nucleinate)
What this could lead to: If it works, this could provide a supportive treatment to help patients better tolerate chemotherapy and other aggressive therapies by reducing infections and blood cell count drops.
What could go wrong: This is a small, completed Phase 2/3 trial with only 75 participants. Results may not apply to all patients, and the drug's safety and effectiveness need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C (HCV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hepatitis C virus infection neoplasm neutropenia tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS C (HCV) MALIGNANT NEOPLASMS TUBERCULOSIS (TB)

More trials for these conditions

Other studies related to the condition(s) this trial covers.